Vect-Horus and RadioMedix announce signing of a Letter of Intent to co-develop a radio-theranostic agent for Glioblastoma

This partnership will marry the expertise of Vect-Horus in targeting tumors with its technology VECTrans® and the know-how of RadioMedix in developing and conducting pre-clinical evaluation and clinical trials with radiopharmaceuticals.

For more information, please follow this link or download the pdf version.